Evidence map›Paper›PMID 40248748›Full record

ArticleInternational journal of general medicine2025

TRIM6 Promotes Cell Cycle and Growth by Modulating p53 Signaling Pathway in Lung Adenocarcinoma.

Xi Lu, Haifeng Wang, Tingting Yu

Abstract read
In one paragraph

Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xi LuDepartment of Thoracic and Abdominal Radiotherapy, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, 830011, People's Republic of China.
Haifeng WangDepartment of Thoracic and Abdominal Radiotherapy, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, 830011, People's Republic of China.
Tingting YuDepartment of Thoracic Oncology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, 830011, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Accumulated evidence suggested that tripartite motif-containing (TRIM) proteins have a pivotal role in cancer progression. The function of TRIM6 remains largely unknown in lung adenocarcinoma (LUAD). This study aimed to clarify the role of TRIM6 in the LUAD pathogenesis. Methods: The genes involved in TRIM were selected by differential gene expression analysis and Cox regression analysis. TRIM6 was identified and verified in LUAD specimens and in paired normal tissues using immunohistochemistry. A correlation analysis was conducted comparing the expression of TRIM6 and clinicopathologic features. The role of TRIM6 in vitro and in vivo was evaluated by cell proliferation assays, cell apoptosis, cell cycle and a tumor xenograft model. Finally, we investigated downstream proteins regulated by TRIM6 by Western blotting. Results: Among TRIM proteins, TRIM6 expression was significantly elevated in LUAD tissues. The prognosis analysis demonstrated that high expression of TRIM6 was associated with unfavorable survival, which was consistent with the findings of Cox regression analysis. Further correlation analysis concluded that high TRIM6 expression was also associated with TNM staging. TRIM6 knockdown suppressed proliferation, induced cell apoptosis and cell cycle arrest in the G2/M phase. Furthermore, the exact effect of TRIM6 on LUAD cells was examined using in vivo experiments. Mechanistically, TRIM6 enhanced the biological capacity of LUAD cells through the p53 signaling pathway. Conclusion: Our study identifies TRIM6 is a potential oncogene and a prognostic target through the regulation of p53 signaling pathway in LUAD.

Indexed as

cell cyclelung adenocarcinomaP53 signaling pathwayproliferationTRIM6

Identifiers

PMID40248748
PMCPMC12005208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.